• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    BullFrog AI's bfPREP™ and bfLEAP® Platforms Deliver Real-World Impact in Eleison Pharmaceuticals Collaboration

    9/8/25 8:00:00 AM ET
    $BFRG
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BFRG alert in real time by email

    Joint oncology conference submission planned and follow-on contract discussion underway

    Validates BullFrog AI's enterprise-grade platform strategy, combining automation and human-in-the-loop oversight for scalable, trustworthy analytics

    GAITHERSBURG, Md., Sept. 08, 2025 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG, BFRGW)) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence ("AI") and machine learning to enable the successful development of pharmaceuticals and biologics, today provided an update on its collaboration with Eleison Pharmaceuticals Inc. ("Eleison"), a Phase 3 oncology company focused on novel chemotherapeutic treatments for rare cancers.

    To support this collaboration, BullFrog AI developed a new data ingestion module, purpose-built to handle the scale and complexity of Eleison's historical clinical data. Originally created to convert more than 10,000 pages of clinical trial PDFs into an OMOP-standardized dataset for Eleison, the module proved so effective that it has since become a standalone commercial offering of BullFrog AI called bfPREP™.

    "Our bfPREP™ module turns legacy and siloed clinical trial data into a strategic asset," said Vin Singh, CEO of BullFrog AI. "In the case of Eleison, we were dealing with a vast amount of complex clinical documentation, the kind of data that typically slows down or derails analytics efforts. With our purpose-built, proprietary technology, we were able to ingest, clean, and standardize that data at scale, transforming it into a foundation for actionable insights. It's a clear demonstration of how our enterprise-grade platforms can handle the volume, variability, and nuance of real-world clinical datasets, positioning BullFrog AI as a highly capable and trusted partner to the pharmaceutical industry."

    Scalable AI-Driven Value Creation

    Following ingestion, BullFrog AI applied feature engineering and AI-enhanced curation to extend the dataset, categorizing diseases, medications, lesion descriptors, and normalizing free text into structured fields. Using a layered approach, where automation handles repeatable tasks and human reviewers ensure accuracy, the Company was able to rapidly scale data preparation while maintaining the integrity and nuance required for clinical decision-making.

    The structured dataset was then deployed into bfLEAP®, BullFrog AI's core analytics engine, to identify data-driven patient subgroups ahead of randomization. These insights may inform both trial design and market positioning, as they illuminate patient segments most likely to benefit from Eleison's therapies.

    "This initiative demonstrates how bfPREP™ and bfLEAP® can improve patient targeting and create meaningful insights to accelerate trial efficiency for pharmaceutical partners. We view this as a strong proof point for the broader application of our platforms across the drug development landscape," added Mr. Singh.

    "We've been impressed by BullFrog's rigor and responsiveness and are extremely pleased with the collaboration to date," said Matt Cromie, MS, VP Clinical Development at Eleison. "We look forward to continuing our efforts together."

    Upcoming Milestones and Expansion Potential

    Encouraged by the progress, BullFrog AI and Eleison are preparing a joint scientific submission to an upcoming oncology conference, which management believes will further validate the commercial value of the Company's AI platforms. In addition, the two companies are exploring further collaboration through a second contract for additional collaboration work.

    "Every milestone in this collaboration strengthens our case for broader adoption of BullFrog AI solutions across the industry," Mr. Singh added. "With the biopharma sector under constant pressure to reduce risk and cost in clinical development, we see significant investor upside in demonstrating that our platforms can deliver both scientific and financial impact."

    About BullFrog AI

    BullFrog AI leverages Artificial Intelligence and machine learning to advance drug discovery and development. Through collaborations with leading research institutions, BullFrog AI uses causal AI in combination with its proprietary bfLEAP® platform to analyze complex biological data, aiming to streamline therapeutics development and reduce failure rates in clinical trials.

    For more information visit BullFrog AI at: https://bullfrogai.com

    About Eleison Pharmaceuticals

    Eleison's mission is to acquire and develop drug candidates with existing and significant safety and efficacy data, with the goal of obtaining regulatory approval and commercializing new therapeutics for patients with life-threatening cancers. In addition to its glufosfamide program, the company has two other programs in late-stage clinical development: ILC for small cell lung cancer and pediatric osteosarcoma, and DBD for brain cancers. Eleison has entered development and marketing partnerships with leading pharmaceutical companies in China, South Korea, and Israel. Founded in 2009, Eleison is headquartered in Princeton, NJ.

    For more information, visit www.eleison-pharma.com.

    Safe Harbor Statement

    This press release contains forward-looking statements. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as "may," "should," "could," "will," "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," or "hopes" or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; our and our partners' ability to market and sell our offerings and services, including BullFrog Data Networks™; our ability to maintain compliance with Nasdaq listing rules; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur.

    Contact:

    Dave Gentry

    RedChip Companies, Inc.

    1-407-644-4256

    [email protected]



    Primary Logo

    Get the next $BFRG alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BFRG

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BFRG
    SEC Filings

    View All

    Bullfrog AI Holdings Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Leadership Update

    8-K - BullFrog AI Holdings, Inc. (0001829247) (Filer)

    8/27/25 4:30:52 PM ET
    $BFRG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Bullfrog AI Holdings Inc.

    10-Q - BullFrog AI Holdings, Inc. (0001829247) (Filer)

    8/13/25 4:59:11 PM ET
    $BFRG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by Bullfrog AI Holdings Inc.

    DEF 14A - BullFrog AI Holdings, Inc. (0001829247) (Filer)

    8/8/25 8:00:16 AM ET
    $BFRG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BFRG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BullFrog AI's bfPREP™ and bfLEAP® Platforms Deliver Real-World Impact in Eleison Pharmaceuticals Collaboration

    Joint oncology conference submission planned and follow-on contract discussion underway Validates BullFrog AI's enterprise-grade platform strategy, combining automation and human-in-the-loop oversight for scalable, trustworthy analytics GAITHERSBURG, Md., Sept. 08, 2025 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG, BFRGW)) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence ("AI") and machine learning to enable the successful development of pharmaceuticals and biologics, today provided an update on its collaboration with Eleison Pharmaceuticals Inc. ("Eleison"), a Phase 3 oncology company focused on novel chemo

    9/8/25 8:00:00 AM ET
    $BFRG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BullFrog AI to Present at BTIG Annual Virtual Biotechnology Conference

    GAITHERSBURG, Md., July 28, 2025 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG, BFRGW)) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence ("AI") and machine learning to enable the successful development of pharmaceuticals and biologics, today announced that Vin Singh, CEO, will participate in a fireside chat and one-on-one meetings at BTIG's Annual Virtual Biotechnology Conference, being held Tuesday, July 29 through Wednesday, July 30. Fireside Presentation Details Date: Wednesday, July 30, 2025 Time: 11:20 a.m. ET To request access to the presentation, contact: USCorporat

    7/28/25 4:30:00 PM ET
    $BFRG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rethinking R&D: BullFrog AI White Paper Outlines New Blueprint for Smarter Drug Development

    From target discovery to trial optimization, bfLEAP™ empowers biopharma teams to predict therapeutic success with greater confidence In a $200B+ market crowded with black-box AI, BullFrog AI's bfLEAP™ delivers what others can't: biologically grounded, composition-aware analytics that guide smarter therapeutic decisions GAITHERSBURG, Md., July 22, 2025 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG, BFRGW)) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence ("AI") and machine learning to enable the successful development of pharmaceuticals and biologics, today announced the release of a new white paper titled "Why

    7/22/25 8:00:00 AM ET
    $BFRG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BFRG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Blacher Joshua was granted 15,000 shares (SEC Form 4)

    4 - BullFrog AI Holdings, Inc. (0001829247) (Issuer)

    8/26/25 4:05:37 PM ET
    $BFRG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Elsey R Don was granted 8,523 shares (SEC Form 4)

    4 - BullFrog AI Holdings, Inc. (0001829247) (Issuer)

    8/26/25 4:05:35 PM ET
    $BFRG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Singh Vininder was granted 75,000 shares, increasing direct ownership by 3% to 2,367,446 units (SEC Form 4)

    4 - BullFrog AI Holdings, Inc. (0001829247) (Issuer)

    8/26/25 4:05:41 PM ET
    $BFRG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BFRG
    Leadership Updates

    Live Leadership Updates

    View All

    BullFrog AI Issues Letter to Stockholders

    GAITHERSBURG, Md., Dec. 27, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG, BFRGW)) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, issued a letter to stockholders from its CEO Vin Singh. Dear Fellow Stockholders, As the year comes to a close, I want to extend my deepest gratitude for your unwavering support and belief in our mission to revolutionize drug development. Your commitment fuels our drive to innovate and achieve transformational milestones. In thinking back on this past year, it is evident that 2024 wa

    12/27/24 8:00:00 AM ET
    $BFRG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BullFrog AI Announces Appointment of Chief Financial Officer

    GAITHERSBURG, Md., Dec. 17, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG, BFRGW)) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced the appointment of Josh Blacher as its Chief Financial Officer (CFO), effective immediately. This appointment comes in the wake of the untimely passing of Dane Saglio, BullFrog AI's former CFO, who recently lost his battle with cancer. "Dane's contributions to BullFrog AI were immeasurable. Beyond his exceptional expertise and dedication, Dane was a trusted advisor and

    12/17/24 4:30:00 PM ET
    $BFRG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BullFrog AI Strengthens Scientific Advisory Board with the Addition of GSK Veteran and Industry Pioneer Dr. John Baldoni

    GAITHERSBURG, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- BullFrog AI, Inc. (NASDAQ:BFRG, BFRGW))) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced the appointment of John Baldoni, Ph.D., to its Scientific Advisory Board. Dr. Baldoni brings over four decades of experience in the pharmaceutical industry, including leadership roles in scientific research and technology-driven drug discovery. Dr. Baldoni's career includes 29 years in R&D at GSK, where he served as Senior Vice President of Platform and Technology Sciences, lea

    10/15/24 7:30:00 AM ET
    $BFRG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BFRG
    Financials

    Live finance-specific insights

    View All

    BullFrog AI and GreenPower Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

    ORLANDO, FL / ACCESSWIRE / April 26, 2024 / RedChip Companies will air interviews with BullFrog AI Holdings, Inc. (NASDAQ:BFRG) and GreenPower Motor Company Inc. (NASDAQ:GP) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, April 27, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:BullFrog AI: https://www.redchip.com/assets/access/bfrg_accessGreenPower: https://www.redchip.com/assets/access/gp_accessIn an exclusive interview, Vin Singh, CEO of BullFrog AI, appears on the RedChip Small Stocks, Big Money™ Show on Bloomberg TV to provide a corporate u

    4/26/24 9:00:00 AM ET
    $BFRG
    $GP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Construction/Ag Equipment/Trucks
    Consumer Discretionary

    ASP Isotopes and Bullfrog AI Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV

    ORLANDO, FL / ACCESSWIRE / October 27, 2023 / RedChip Companies will air interviews with ASP Isotopes Inc. (NASDAQ:ASPI) and BullFrog AI Holdings, Inc. (NASDAQ:BFRG)(NASDAQ:BFRGW) on The RedChip Small Stocks Big Money® Show, a sponsored program on Bloomberg TV, this Saturday, October 28, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:ASP Isotopes: https://www.redchip.com/assets/access/aspi_accessBullfrog AI: https://www.redchip.com/assets/access/bfrg_accessPaul Mann, CEO, of ASP Isotopes appears on the RedChip Small Stocks Big Money® Show on Bloomberg TV to provide a corporate update. ASP Isoto

    10/27/23 9:00:00 AM ET
    $ASPI
    $BFRG
    Major Chemicals
    Industrials
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RedChip Launches 'Small Stocks, Big Money' Podcast

    New podcast series shines a spotlight on undervalued small-cap and microcap stocksORLANDO, FL / ACCESSWIRE / August 2, 2023 / RedChip Companies, a renowned international investor relations firm specializing in microcap and small-cap companies,announce the launch of its much-anticipated podcast series, "Small Stocks, Big Money."Hosted by RedChip CEO Dave Gentry and Associate Director Barrett Boone, the "Small Stocks, Big Money" podcast aims to offer a first-hand look at undiscovered small-cap and microcap stocks before they catch the attention of bigger Wall Street players. The series features in-depth interviews with executives from some of the top names in smaller cap stocks, providing list

    8/2/23 12:45:00 PM ET
    $BFRG
    $LTRN
    $RVPH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments
    Pharmaceuticals and Biotechnology